Objective-Mutations in the hematopoietic transcription factor RUNX1 cause thrombocytopenia and impaired platelet function. In a patient with a heterozygous mutation in RUNX1, we have described decreased platelet pleckstrin phosphorylation and protein kinase C-(PKC-, gene PRKCQ) associated with thrombocytopenia, impaired platelet aggregation, and dense granule secretion. Little is known regarding regulation of PKC-in megakaryocytes/platelets. We have addressed the hypothesis that PRKCQ is a direct transcriptional target of RUNX1. Methods and Results-In a chromatin immunoprecipitation assay using megakaryocytic cells, there was RUNX1 binding in vivo to PRKCQ promoter region Ϫ1225 to Ϫ1056 bp containing a RUNX1 consensus site ACCGCA at Ϫ1088 to Ϫ1069 bp; an electrophoretic mobility shift assay showed RUNX1 binding to the specific site. In RUNX1 overexpression studies, PKC-protein expression and promoter activity were enhanced; mutation of RUNX1 site showed decreased activity even with RUNX1 overexpression. Lastly, PRKCQ promoter activity and PKC-protein were decreased by short interfering RNA knockdown of RUNX1. Conclusion-Our results provide the first evidence that PRKCQ is regulated at the transcriptional level by RUNX1 in megakaryocytic cells and a mechanism for PKC-deficiency associated with RUNX1 haplodeficiency. (Arterioscler Thromb Vasc Biol. 2011;31:00-00.) Figure 5. Inhibition of PKC-protein and promoter by RUNX1 siRNA in HEL cells. A, Immunoblotting of HEL cell lysates showing ␤-actin, RUNX1, and PKC-. RUNX1 siRNA inhibited PKCand RUNX1 protein and promoter activity.
P rotein kinase C (PKC, gene PRKCQ) signaling is a critical aspect of megakaryocytic (MK) differentiation, 1 proplatelet formation, 2,3 platelet function, and thrombus formation. 4 -8 Platelets possess several PKC isozymes, including classical PKCs ␣, ␤I, and ␤II; novel PKCs ␦, , , and ; and atypical PKC , and , and the specific roles of these isozymes in platelets and thrombus formation are being defined. 4 -8 PKC in synergy with Ca ϩ elevation regulate dense and ␣-granule secretion on platelet stimulation by thrombin, thromboxane A2, and ADP. 9 -11 PKCs play a role in ␣ IIb ␤ 3 activation by promoting conformational changes required for fibrinogen binding and platelet aggregation. 12, 13 The activated integrins themselves stimulate 1 or more PKC isozymes, leading to filopodia formation and platelet spreading. 14, 15 Evidence is emerging for distinct roles of PKC isoforms in platelet activation and thrombus formation. PKC-␣ has been proposed as a key enzyme regulating ␣ and dense granule secretion, platelet aggregate formation, and thrombus formation. 11, 16, 17 In mouse platelets, PKC-␤ positively regulates outside-in ␣IIb␤3 signaling, platelet spreading on fibrinogen, and collagen-induced thrombus formation. 4, 14 Gilio et al 4 showed that PKC-␦ negatively regulates thrombus formation. Mouse platelets deficient in PKC-␦ have enhanced filopodia formation and collagen-induced platelet aggregation 18 ; dense granule secretion induced by activation of GPVI was normal in 1 study 18 but enhanced in another, along with enhanced thromboxane A2 formation. 19 In the latter report, interestingly, dense granule secretion induced by the PAR4 agonist was reduced, indicating an agonist-specific differential effect of PKC-␦. PKC--deficient murine platelets have revealed defective filopodia formation and spreading on fibrinogen. 15, 20 PKC--deficient mice have been reported to have impaired hemostasis with prolonged bleeding times and decreased agonist-stimulated platelet aggregation, dense and ␣-granule secretion, ␣IIb␤3 activation, and thromboxane A2 production. 8, 21 Other studies have found that PKC--deficient mice have enhanced GPVI-mediated ␣-granule secretion and inside-out activation of ␣IIb␤3, along with enhanced thrombus formation on collagen. 20 Soriani et al 15 have reported that PKC-plays a role in outside-in ␣II␤3 signaling but not in inside-out signaling. Although these studies are conflicting in some aspects (likely because of different experimental conditions), they advance the concept that PKC-plays an important role in platelet function.
We have reported detailed studies on a patient [22] [23] [24] with inherited thrombocytopenia; decreased platelet aggregation, secretion, and GPIIb-IIIa activation; impaired phosphorylation of pleckstrin and myosin light chain; and decreased platelet PKC-(protein and mRNA) associated with a mutation in RUNX1. RUNX1 is a transcription factor that plays a major role in hematopoiesis and megakaryopoiesis. [25] [26] [27] It is composed of 2 subunits; the ␣-subunit (RUNX1) is the DNA binding element of the complex and recognizes the DNA sequence TGT/cGGT. CBF␤, the ␤ subunit, stabilizes RUNX1 binding to DNA but without direct DNA contact. RUNX1 mutations are associated with familial, autosomaldominant thrombocytopenia; platelet dysfunction; and predisposition to acute leukemia. 28, 29 On the basis of the decreased platelet PKC-in our patient, we hypothesized that platelet/ megakaryocyte PKC-is regulated at the transcriptional level by RUNX1 and constitutes the mechanism for PKC-deficiency. Despite the important role of PKC-signaling in platelet function, very little is known about its transcriptional regulation in MK cells. In the present studies, we provide the first evidence that PKCis a direct transcriptional target of RUNX1. We have recently shown that RUNX1 regulates ALOX12, 30 MYL9, 31 and PF4. 32 The present studies extended this to PRKCQ and underscored the complex nature of alterations in platelets/megakaryocytes in human RUNX1 haplodeficiency.
Materials and Methods

Patient Information
We have previously described [22] [23] [24] the clinical presentation and studies in this 24-year-old white male, documenting decreased agonist stimulated platelet aggregation, secretion, GPIIb-IIIa activation, and pleckstrin and myosin light chain phosphorylation; platelet PKC-level was decreased. The patient has a single point mutation in RUNX1, in intron 3 at the splice acceptor site for exon 4, leading to a frameshift with premature termination in the conserved Runt homology domain. 23
Materials
All chemicals, including phorbol 12-myristate 13-acetate (PMA), were purchased from Sigma-Aldrich (St Louis, MO) or Fisher Scientific (Pittsburgh, PA). GoTaq Green PCR Master Mix, luciferase reporter vectors pGL3-Basic and pRL-TK, and the Dual Luciferase Assay System were from Promega (Madison, WI). Polymerase chain reaction (PCR) primers and infrared dye-labeled probes for the electrophoretic mobility shift assay (EMSA) were purchased from Integrated DNA Technologies, IDT (Coralville, IA). PCR products were sequenced by capillary electrophoresis and fluorescent dye terminator detection on an ABI3730xl DNA analyzer (Genewiz, South Plainfield, NJ). Recombinant RUNX1 protein, RUNX1 expression plasmid RUNX1-pCMV6-XL4, empty expression vector pCMV6-XL4, and transfection agent Turbofectin 8.0 were from Origene Technologies (Rockville, MD).
Cell Lines and Cell Culture
Human erythroleukemia (HEL) cell line from American Type Cell Culture (Rockville, MD) was cultured in RPMI-1640 medium (Mediatech) in the presence of 10% fetal bovine serum and antibiotics (Mediatech). During induction, HEL cells were grown in 10 nmol/L PMA.
Chromatin Immunoprecipitation Assay
The chromatin immunoprecipitation (ChIP) assay was performed using HEL cells (1ϫ10 8 ) treated with PMA for 24 hours and the ChIP-IT kit (Active Motif, Carlsbad, CA) as described. 31 Sheared fragments were immunoprecipitated with anti-RUNX1 antibody (sc-8564x, Santa Cruz Biotechnology, Santa Cruz, CA) or the negative control IgG antibody supplied in the kit. We amplified 3 regions (Ϫ665 to Ϫ478 bp, Ϫ1225 to Ϫ1056 bp, and Ϫ1468 to Ϫ1277 bp) of the PRKCQ promoter with specific primers.
EMSA
Nuclear extracts were prepared from PMA-treated HEL cells according to Dignam et al. 33 Nuclear protein-DNA interactions were performed using PKC-infrared dye-labeled double-stranded oligos and the Odyssey Infrared EMSA Kit (Li-Cor Biosciences, Lincoln, NE). PKC-wild-type (Wt) probes used to examine RUNX1 binding to each consensus site (in bold) and their mutants generated by deletions in RUNX1 sites (underlined) were as follows: Wt probe I (Ϫ585 to Ϫ566) with site I, 5Ј-CAAATGCCTGGGGTAGGTCA-3Ј, and its mutant 5Ј-CAAATGC CTGGGGTAGGTCA-3Ј; Wt probe II (Ϫ618 to Ϫ599) with site II, 5Ј-GAACGATG ACCCCAGGACAG-3Ј, and its mutant 5Ј-GAACGATGACCCCAGGACAG-3Ј; Wt probe III (Ϫ1088 to Ϫ1070) with site III, 5Ј-ATGAGCCACCGCA-CCTGGCC-3Ј, and its mutant 5Ј-ATGAGC CACCGCAC CTGGCC-3Ј; Wt probe IV (Ϫ1319 to Ϫ1300) with site IV, 5Ј-CAGTGCAGTGGTGAGATCTC-3Ј, and its mutant 5Ј-CAGTGCAGTGGTGAGATCTC-3Ј; and Wt probe V (Ϫ1442 to Ϫ1423) with site V, 5Ј-ACCTCTGAGGTTCTTTTTAG-3Ј, and its mutant 5Ј-ACCTCTGAGGTTCTTTTTAG-3Ј. Three micrograms of nuclear extract and 50 fmol of infrared-labeled probe were used in binding reactions performed on ice for 30 minutes. Oligonucleotide competitors were added 30 minutes before the labeled probe was added. For supershift assays, RUNX1 antibody (sc-8563x) or control IgG (Santa Cruz Biotechnology) was preincubated with nuclear protein before labeled probe was added. In addition, EMSA was performed with recombinant RUNX1 protein (200 ng) to see its binding to PKCprobes. Binding reaction was performed on ice for 1 hour in a buffer containing 0.6 mmol/L HEPES, pH 8.0, 1 mmol/L dithiothreitol, 0.01% Triton X-100, 2% glycerol, 5 g/L bovine serum albumin, and 100 mmol/L NaCl. For supershift studies, anti-RUNX1 antibody (sc-8564x) or control IgG (Santa Cruz Biotechnology) was preincubated for 30 minutes on ice with recombinant RUNX1 protein before the addition of labeled probe. Binding complexes were separated by electrophoresis on native 5% Trisborate-EDTA gels (Bio-Rad) and detected using the Odyssey Infrared Imaging System (Li-Cor Biosciences).
Construction of Luciferase Reporter Plasmids
The PRKCQ promoter region (Ϫ1085 to Ϫ206 bp) was amplified by a standard PCR from human genomic DNA using modified primers incorporated with restriction sites XhoI in the forward primer and HindIII in the reverse primer. The PCR product was cloned into pCR 2.1 TOPO TA cloning vector (Invitrogen, Carlsbad, CA), digested with XhoI and HindIII enzymes, and cloned into appropriate sites of luciferase vector, pGL3-Basic. The primer sequences of Wt construct were as follows: forward at Ϫ1085 to Ϫ1068, 5Ј-aaactcgagGAG-CCACCGCACCTGGCC-3Ј with RUNX1 site (in bold), and reverse at Ϫ221 to Ϫ206 5Ј-cacaagcttGGTTGCGCCCTGGAGC-3Ј (lowercase letters indicate flanking sequences). The mutant construct was generated by mutating the RUNX1 site by deletions (bold and underlined) in the forward primer 5Ј-aaactcgagGAGCCACCGCA-CCTGGCCЈ and using the same (Ϫ221 to Ϫ206) reverse primer as described above. PCR products were confirmed by DNA sequencing before cloning.
RUNX1 Overexpression
HEL cells (1ϫ10 6 ) were cotransfected with equal amounts of Wt PRKCQ reporter construct (Ϫ1085 to Ϫ206-Luc) and
RUNX1expression plasmid, RUNX1-pCMV6-XL4, or empty vector pCMV6-XL4 (1 g each), along with an internal control, pRL-TK containing the Renilla luciferase gene (20 ng), using the Turbofectin 8.0 transfection reagent. Wt PRKCQ construct alone was cotransfected with pRL-TK. Mutant PRKCQ reporter transfections were also performed in a similar manner. In parallel, promoterless empty vector pGL3-Basic was transfected as a control. After transfection for 3 to 4 hours at 37°C in 5% CO 2 , medium containing PMA (10 nmol/L) was added to the transfection mixture. After 48 hours, cells were lysed, and luciferase activity was measured using Dual Luciferase Assay System (Promega). Promoter activity was expressed as firefly luciferase activity/Renilla luciferase activity relative to that of the empty vector. All transfection experiments were performed 3 times in triplicate. RUNX1 and PKC-were assessed in HEL cell lysates by immunoblotting.
RUNX1 Knockdown by Its Short Interfering RNA
HEL cells (5ϫ10 5 ) were transfected with 400 nmol/L RUNX1 short interfering RNA (siRNA) pool (sc-37677) or unrelated mock siRNA (Santa Cruz Biotechnology) using the siRNA transfection reagent system (Santa Cruz Biotechnology). 31 After 5 hours of transfection, medium containing 20% fetal bovine serum and 50 nmol/L of PMA was added to the cells. On the following day, the medium was replaced with medium containing 10% serum and 50 nmol/L PMA. Cells were harvested at 48 hours. The effect of RUNX1 siRNA was examined by immunoblot analysis. In parallel, HEL cells were cotransfected with Wt PRKCQ construct and mock or RUNX1 siRNAs along with an internal control (pRL-TK) as described above. Luciferase activity was measured in HEL cell lysates using the Dual Luciferase Assay System (Promega).
Immunoblotting
Whole cell lysates (30 to 40 g) from cotransfected HEL cells were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to Odyssey nitrocellulose membranes (Li-Cor Biosciences), and probed with the antibodies against RUNX1 (sc-8563), PKC-(sc-1875), and actin (sc-1616R) or ␤-actin (sc-47778) from Santa Cruz Biotechnology. Specific protein expressions were detected with infrared-labeled secondary antibodies using the Odyssey Infrared Imaging System (Li-Cor Biosciences).
Bioinformatics
Potential binding sites for transcription factors were analyzed by the computer program TFSEARCH (http://mbs.cbrc.jp/research/db/ TFSEARCH.html).
Results
Binding of RUNX1 to the PRKCQ Promoter by ChIP
Analysis of the PRKCQ promoter region (2075 bp from the ATG) using TFSEARCH revealed 5 RUNX1 consensus sites: Ϫ577 to Ϫ572 (site I), Ϫ610 to Ϫ605 (site II), Ϫ1081 to Ϫ1076 (site III), Ϫ1313 to Ϫ1308 (site IV), and Ϫ1437 to Ϫ1432 (site V) ( Figure 1A ). We performed immunoprecipitations on chromatin samples from PMA-treated HEL cells using an anti-RUNX1 antibody to identify an endogenous interaction between RUNX1 and the PRKCQ gene. PCR primers were designed to amplify PKCregions Ϫ665 to Ϫ478 bp (containing sites I and II), Ϫ1225 to Ϫ1056 bp (containing site III), and Ϫ1468 to Ϫ1277 bp (containing sites IV and V). These primers were used to amplify HEL cell chromatin enriched by anti-RUNX1 antibody. Only region Ϫ1225 to Ϫ1056 bp (containing site III) was enriched by RUNX1 antibody ( Figure 1B) . These observations indicate that RUNX1 binds in vivo to site III but not to other sites under the conditions studied.
Binding of RUNX1 to Consensus Sites on the PRKCQ Promoter by EMSA
EMSA was performed using HEL cell nuclear extracts and Wt probe I, which contains RUNX1 consensus site I ( Figure  2A ). Protein binding occurred with probe I (Figure 2A, lane  2) . Binding was not altered by competition with the mutant probe with mutation of RUNX1 site (lane 3) but was lost by . Figure 2B shows nuclear protein binding to probe containing consensus site II (lane 2). This binding was competed by excess unlabeled probe (lane 3) but not by RUNX1 antibody (6 g) (lane 4). Competition studies were performed with 2, 4, and 6 g of antibody, but binding was not affected. It was not altered by normal IgG (lane 5). Lane 6 shows no effect on binding by competition with excess unlabeled mutant probe with the RUNX1 site mutated. These findings suggest that the observed protein binding to the probe with site II is not due to RUNX1, and the findings are in line with those of ChIP (Figure 1) . Figure 2C shows protein binding to probe III with RUNX1 consensus site III (lane 1); this was abolished by competition with excess unlabeled probe (lane 2). Binding was inhibited by RUNX1 antibody (lanes 3 and 4) but not by IgG (lane 5). DNA-protein binding was not altered by competition with the mutant probe (lane 6). Lane 7 shows labeled probe alone. These data indicate that RUNX1 binds to site III. EMSA performed on probes with site IV or V showed no protein binding (data not shown). Together, these results indicate that RUNX1 binds to sites I and III, as measured by EMSA.
Binding Studies With Recombinant RUNX1
To further establish that RUNX1 binds to PKC-probes I and III, we performed studies using recombinant RUNX1 protein. Figure 3A shows RUNX1 binding to probe I, containing site I (lane 2). This binding was competed by excess unlabeled probe (lane 3), unaffected by normal IgG (lane 4), but supershifted by anti-RUNX1 antibody (lane 5). Similar results were obtained with probe containing site III ( Figure 3B) . These data provide further support that RUNX1 binds to sites I and III.
Enhancement of PRKCQ Promoter Activity and PKC-Protein by Overexpression of RUNX1
Immunoblot analysis of HEL cells transfected with RUNX1-pCMV6 expression plasmid revealed enhanced expression of RUNX1 and PKC-( Figure 4A ). Promoter activity of Wt PRKCQ construct (Ϫ1085 to Ϫ206-Luc) containing sites I, II, and III was not increased in the presence of empty vector pCMV6-XL4 ( Figure 4B ). It was markedly enhanced in the presence of RUNX1 expression plasmid RUNX1-pCMV6-XL4. The ChIP studies (Figure 1 ) showed in vivo binding of RUNX1 to site III only. Therefore, we studied the effect of mutating this site. A mutant promoter with site III mutated (but with sites I and II intact) showed complete loss of activity. Overexpression of RUNX1 did not increase activity, indicating that site III is involved in regulating promoter activity, but sites I and II are not. These findings complement the results of ChIP analysis and EMSA.
Reduction of PRKCQ Promoter Activity and PKC-Protein by RUNX1 siRNA
Immunoblot analysis showed that both RUNX1 and PKCwere decreased by RUNX1 siRNA (Figure 5A ). PRKCQ promoter (Ϫ1085 to Ϫ206-Luc) activity was markedly reduced with RUNX1 siRNA (Figure 5B ).
Discussion
The major novel finding in our studies is that the transcription factor RUNX1 regulates the PRKCQ gene in MK cells. In silico analyses of the PRKCQ promoter (up to Ϸ2075 bp) revealed 5 consensus sites for RUNX1 ( Figure 1A) . ChIP studies showed enrichment of the region (Ϫ1225 to Ϫ1056) containing RUNX1 site III but not regions with other sites (Figure 1 ), suggesting in vivo binding of RUNX1 to site III. EMSA with nuclear extracts and recombinant RUNX1 (Figures 2 and 3) showed RUNX1 binding to site III. Mutation of RUNX1 site III abolished promoter activity, indicating its functional importance; overexpression of RUNX1 increased RUNX1 and PKC-proteins and promoter activity, which was lost on mutation of site III (Figure 4 ). RUNX1 siRNA inhibited PKC-protein expression and PRKCQ promoter activity ( Figure 5 ). Together, these findings indicate that PKC-is regulated at the transcriptional level by RUNX1 and that site III is crucial for transcriptional control of PRKCQ in MK cells. The studies presented here were performed in HEL cells treated with PMA to induce MK differentiation, a widely used model for studies on megakaryocyte biology. 34, 35 That these findings are directly relevant to platelet PKCexpression is supported by the findings 36 in our patient with RUNX1 haplodeficiency, which showed that PKC-protein and mRNA are decreased in platelets, the primary cells. In addition, we have shown 22 that pleckstrin phosphorylation was decreased in the platelets, which provides strong evidence for a functional consequence of the diminished PKCexpression. The present studies provide a cogent explanation for decreased platelet PKC-associated with RUNX1 haplodeficiency. Previous studies in U937 cells have shown PKC-␤ to be a direct RUNX1 target 37 ; platelet PKC-␤ was normal in our patient. 23 RUNX1 haplodeficiency is associated with familial thrombocytopenia, predisposition to acute leukemia, impaired megakaryopoiesis, 28 and impaired platelet function on activation. 22, 28, 29 Mice lacking RUNX1 have a complete absence of fetal liver-derived hematopoiesis 38 and impaired MK maturation 27 ; Runx1 haplodeficiency is associated with de-creased platelet number. 39 Multiple lines of evidence link PKC to critical aspects of MK differentiation. 1, 40 Phorbol esters activate PKC and induce progenitor cells to differentiate along megakaryocyte lines and express megakaryocyte/ platelet proteins. [41] [42] [43] In human progenitors, PKC-exhibits a lineage-restricted expression being expressed in megakaryocytes and erythroblasts but not granulocytes/monocytes. 44 Jacquel et al 40 have proposed that specific PKC isoforms, including PKC-, may not be able to induce MK differentiation alone but that more than 1 PKC isoform may be required for the differentiation process. The specific role of PKC-in megakaryopoiesis and in platelet formation needs to be defined. Interestingly, dominant-negative inhibition of PKC-delays cell cycle progression in vascular endothelial cells. 45 Platelet functional abnormalities constitute a hallmark of RUNX1 mutations. 22, 28, 29 We postulate that the deficiency of platelet PKC-arising secondary to the RUNX1 haplodeficiency contributes to the functional defect shown in our patient's platelets, including in aggregation, secretion, ␣IIb␤3 activation, and cytoskeletal reorganization, 22,31 all of which have been noted in studies in murine PKC--deficient platelets. 8, 21 Moreover, pleckstrin is a major substrate phosphorylated by PKC in platelets 46, 47 and this phosphorylation was impaired in our patient. 22 Pleckstrin-deficient mouse platelets showed marked defects in PKC-mediated exocytosis of dense and ␣ granules, ␣IIb␤3 activation, actin assembly, and aggregation, 48 which provide further support for a potential role of PKC-in the platelet dysfunction observed in our patient. Although we propose that PKC-deficiency contributes to the functional defect in RUNX1 haplodeficiency, the magnitude of PKC-'s role remains to be delineated, particularly because RUNX1 regulates several other genes also recognized to regulate platelet responses. As shown by us, these include ALOX12 (12-lipoxygenase), 30 MYL9 (myosin light chain), 31 PF4 (platelet factor 4), 32 and possibly others. 24 Overall, the concept emerging is that RUNX1 haplodeficiency-associated platelet dysfunction and thrombocytopenia arise from the interactions involving multiple genes. Studies in RUNX1 haplodeficiency provide an opportunity to unravel the role in platelets/MK of various RUNX1-regulated genes and proteins, including those that are currently not recognized to have a role in platelets but are downregulated.
In summary, our studies reveal that PRKCQ is regulated by RUNX1 in megakaryocytes/platelets and provide an explanation for the decreased PKC-expression in RUNX1 haplodeficiency. RUNX1 dysregulation of PRKCQ in megakaryocytes is an important aspect of the abnormal platelet production and function associated with human RUNX1 mutations and is an area for further investigation to unravel the mechanisms leading to defects in platelet production and function.
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